Related Experiment Videos

Drug therapy for chronic heart failure due to left ventricular systolic dysfunction. II. Diuretics

Philip Fortuna1, Inês Reis, Raquel Ascenção

  • 1Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina de Lisboa, Lisboa, Portugal.

Revista Portuguesa De Cardiologia : Orgao Oficial Da Sociedade Portuguesa De Cardiologia = Portuguese Journal of Cardiology : an Official Journal of the Portuguese Society of Cardiology
|October 31, 2008
PubMed

Insights

Diuretics are essential for managing fluid retention in chronic heart failure (CHF). However, they alone cannot ensure long-term clinical stability for patients with left ventricular systolic dysfunction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Diuretics, especially loop diuretics, are standard first-line therapy for chronic heart failure (CHF).
  • Aldosterone antagonists (spironolactone, eplerenone) are increasingly used in CHF but are not universally classified as diuretics.
  • Fluid retention is a key issue in CHF management.

Purpose of the Study:

  • To review current evidence on diuretic use in CHF with left ventricular systolic dysfunction.
  • To assess the role of diuretics in managing fluid retention and clinical stability.

Main Methods:

  • Review of large randomized controlled trials.
  • Analysis of systematic reviews and meta-analyses from secondary sources.

Main Results:

  • Diuretics effectively reduce fluid retention in CHF.
  • Isolated diuretic therapy has limitations in maintaining long-term clinical stability.
  • Evidence focuses on CHF with left ventricular systolic dysfunction.

Conclusions:

  • Diuretics are crucial for symptom management in CHF.
  • Further research and combination therapies may be needed for sustained clinical stability in CHF patients.

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...